Positive End of Phase 2 discussion with FDA, including alignment on Phase 3 design Bayley-4 expressive communication selected as Phase 3 study primary endpoint Initiation of ION582 Phase 3 study...

Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its market-leading portfolio to advance cancer research from target discovery to personalized medicine and cell therapy...

Treatment with TPN-101 showed clinical benefits on key clinical outcome measures, including the Revised ALS Functional Rating Scale (ALSFRS-R) and Slow Vital Capacity (SVC) TPN-101 also had...

Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced that the...

Industry Veteran Raj Ananthanpillai will discuss how to identity, prevent and investigate insider threats to safeguard organizational assets and share best practices and compliance strategies...